Summary This study looked at the performance of the heart as they followed 31 patients, each undergoing a course of 60 hyperabric sessions with the goal of improving cognitive performance. Of these 31 patients, 39% were diagnosed with heart disease, [..]
Leading National TMS provider—more locations, more doctors, more experience, more success!
May 21
New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System(R) induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD) during the acute phase of therapy, which were maintained through one year of treatment. At the end of acute treatment, 62 percent of patients achieved symptomatic improvement while 41 percent reported complete remission. At 12 months, 68 percent of patients achieved symptomatic improvement while 45 percent reported complete remission. Maintenance of benefit was observed under a pragmatic regimen of continuation antidepressant medication and access to TMS reintroduction for symptom recurrence.
Insurance coverage is widely available
Insurance Coverage Information
Patient Self Assessment & Tools
TMS Information for Practitioners
APA Guidelines
TMS Success Stories
NEWS / RESEARCH
